phenethyl isothiocyanate has been researched along with vorinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhalla, K; Chen, G; Fiskus, W; Garcia-Manero, G; Hu, Y; Huang, P; Jia, Y; Keating, M; Lu, W; Wei, Y; Yang, H; Zhang, H; Zhang, W | 1 |
| Ding, L; Huang, R; Pelicano, H; Wen, T; Yin, R; Zeng, J; Zhang, W | 1 |
2 other study(ies) available for phenethyl isothiocyanate and vorinostat
| Article | Year |
|---|---|
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.
Topics: Antioxidants; Base Sequence; Cell Line, Tumor; Cell Survival; DNA Primers; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Isothiocyanates; Leukemia; Leukemia, Myeloid; NADPH Oxidases; NF-E2-Related Factor 2; Oxidation-Reduction; Reactive Oxygen Species; Tumor Cells, Cultured; U937 Cells; Vorinostat | 2010 |
Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Glutathione; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Isothiocyanates; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Oxidation-Reduction; Reactive Oxygen Species; Vorinostat | 2015 |